Sarepta Therapeutics Inc (SRPT): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Sarepta Therapeutics ( SRPT) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.8%. By the end of trading, Sarepta Therapeutics fell $1.59 (-5.5%) to $27.58 on light volume. Throughout the day, 854,039 shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 2.6 million shares. The stock ranged in price between $27.47-$29.52 after having opened the day at $29.33 as compared to the previous trading day's close of $29.17. Other companies within the Health Care sector that declined today were: Chelsea Therapeutics International ( CHTP), down 36.4%, Anika Therapeutics ( ANIK), down 21.2%, CombiMatrix Corporation ( CBMX), down 13.6%, and Spherix ( SPEX), down 12.4%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of serious and life-threatening rare and infectious diseases. Sarepta Therapeutics has a market cap of $761 million and is part of the drugs industry. Shares are up 3815.4% year to date as of the close of trading on Tuesday. Currently there are four analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Novogen ( NVGN), up 20.3%, Cyclacel Pharmaceuticals ( CYCC), up 19.1%, ARCA biopharma ( ABIO), up 14.8%, and Hooper Holmes ( HH), up 10.3%, were all gainers within the health care sector with Shire ( SHPG) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

Holiday Special: Subscribe to Action Alerts PLUS to see how Jim Cramer trades his $2.5 Million+ portfolio for 51% off the list price. Your first 14-days are FREE: Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Sarepta Therapeutics Chart Patterns Look Good

Verastem Shares Are Exploding 50% -- Here's Why

Watch the Key Technical Levels

Net Seller, but Itching to Put More Cash to Work